Abstract 1956
Background
Fatigue is the most common and distressing symptom of which castration resistant prostate cancer (CRPC) patients complain. The little evidence of fatigue prevalence, intensity and interference with daily activities in advanced prostate cancer that exists is mainly restricted to post-docetaxel setting with Abiraterone Acetate (AA). The VITAL study examines the prevalence and intensity of cancer-related fatigue (CRF) in CRPC.
Methods
cross-sectional study of CRPC patients including chemo-naïve metastatic (mCRPC) or high risk M0CRPC (PSADT ≤ 10mo) in routine clinical practice. Fatigue and Quality of Life (QoL) data were collected using validated patient self-reported questionnaires(BFI-SF and FACT-G/P). Fatigue correlation with both patient's and physiciańs perception was assessed.
Results
235 patients were recruited (Jan-Sept 2015). Median age: 75.1 (46.2-92.4), median PSA: 17.8 ng/ml (0-2000), metastatic disease: 68.5%, ECOG 0-1: 90.6%. There was a high prevalence of fatigue (M1:73.9%; M0: 74.3%), with 38.3% of the patients having moderate or severe fatigue. High concordance existed between fatigue physiciańs and patient's perception (Kappa index: 0.818). Cardiovascular and respiratory disorders were associated with an increase of fatigue in the multivariate analysis (OR: 4.7 and 3.6 respectively, p
Conclusions
Our data show a high prevalence and intensity of fatigue and impact in QoL in chemo-naïve CRPC patients. The study highlights the relevance of fatigue awareness and its management in CRPC patients. Table.
FACT-G total score | FACT-P total score | |||||
---|---|---|---|---|---|---|
FATIGUE | Mean | SD | N | Mean | SD | N |
Abscence | 88.0 | 13.3 | 60 | 127.7 | 16.9 | 60 |
Mildly | 79.3 | 12.9 | 84 | 110.1 | 16.3 | 84 |
Moderate | 71.5 | 14.7 | 64 | 110.8 | 19.3 | 64 |
Severe | 63.2 | 19.2 | 25 | 87.7 | 25.1 | 25 |
p-valor* | Clinical trial identificationLegal entity responsible for the studyJannsen-Cilag, Spain FundingJanssen-Cilag, Spain DisclosureAll authors have declared no conflicts of interest. Resources from the same session4099 - A first-in-human (FIH) phase I/II, dose escalation, pharmacokinetic (PK) study to assess the safety and tolerability of VAL-201 in patients with advanced prostate cancer (APC) and other advanced solid tumoursPresenter: Rebecca Kristeleit Session: Poster display Resources: Abstract 4130 - Response to savolitinib (AZD6094/HMPL-504, a potent and selective MET inhibitor) in a papillary renal cell carcinoma patient harbouring a novel MET activating mutationPresenter: Melanie Frigault Session: Poster display Resources: Abstract 4141 - Qualitative and quantitative differences in a set of criteria for histological grading of colorectal cancerPresenter: Taras Savchyn Session: Poster display Resources: Abstract 4167 - The comparison between TP53 gene polymorphisms (c.[215G > C]) homozygotes and heterozygotes in breast cancer patients: a clinicopathological analysisPresenter: Joanna Huszno Session: Poster display Resources: Abstract 4205 - MicroRNAs as biomarkers of resistance to HER2 inhibitors in combination with chemotherapy in gastro-oesophageal cancer cell linesPresenter: Hazel Lote Session: Poster display Resources: Abstract 4208 - Initial first-in-human phase 1 results of PTC596, a novel small molecule that targets cancer stem cells (CSCs) by reducing BMI1 protein levelsPresenter: Geoffrey Shapiro Session: Poster display Resources: Abstract 4276 - Phase II studies of AZD1775, a WEE1 kinase inhibitor, and chemotherapy in non-small-cell lung cancer (NSCLC): Lead-in cohort resultsPresenter: David Spigel Session: Poster display Resources: Abstract 4313 - Survival patterns of T2 & T3 breast cancer according to different modalities of treatment in the United StatesPresenter: Mohamed Ramadan Session: Poster display Resources: Abstract 4322 - Suppression of oncogene transcription - PNA as targeted cancer therapy for BRAF-V600E mutant melanomaPresenter: Jeffrey Rothman Session: Poster display Resources: Abstract 4326 - Phase 1 dose-escalation study of the folic acid-tubulysin small-molecule drug conjugate (SMDC) folate-tubulysin EC1456: Study updatePresenter: Jasgit Sachdev Session: Poster display Resources: Abstract This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
|